In addition, several cell‐cycle‐related biological pathways, including p53 signaling, G2/M DNA damage checkpoint regulation, checkpoint kinase (CHK) proteins in cell‐cycle checkpoint control, chromosomal replication, mitotic roles of polo‐like kinase, aminoacyl‐tRNA biosynthesis, and cyclins and cell‐cycle regulation, were among the most significantly altered pathways in both pancreatic cell lines following GW3965 treatment, corroborating the importance of LXR agonists in cell‐cycle modulation in pancreatic cancer. The gene discussed is TP53; the disease is familial pancreatic carcinoma.